| Literature DB >> 31354818 |
Holly A Szukis1, Bo Qin2, Cathleen Y Xing1, Michelle Doose1, Baichen Xu2, Jennifer Tsui2,3, Yong Lin1,4, Kim M Hirshfield5, Christine B Ambrosone6, Kitaw Demissie1,2,7, Chi-Chen Hong6, Elisa V Bandera1,2, Adana A M Llanos1,2.
Abstract
Mammogram-detected breast cancers have a better prognosis than those identified through clinical breast exam (CBE) or through self-detection, primarily because tumors detected by mammography are more likely to be smaller and do not involve regional nodes. In a sample of 1,322 Black women, aged 40-75 years, diagnosed with breast cancer between 2002 and 2016, we evaluated factors associated with CBE and self-detection versus screening mammogram as the initial mode of breast cancer detection, using multivariable logistic regression models. Compared with screening mammogram, history of routine screening mammogram (OR 0.20, 95% CI: 0.07, 0.54) and performance of breast self-examination (BSE) (OR 0.31, 95% CI: 0.13, 0.74) before diagnosis were associated with lower odds of CBE as the initial mode of detection, while performance of CBEs before diagnosis (OR 11.04, 95% CI: 2.24, 54.55) was positively associated. Lower body mass index (<25.0 kg/m2 vs. ≥35.0 kg/m2: OR 2.46, 95% CI: 1.52, 3.98), performance of BSEs before diagnosis (less than once per month: OR 4.08, 95% CI: 2.45, 6.78; at least monthly: OR 4.99, 95% CI: 3.13, 7.97), and larger tumor size (1.0-2.0 cm vs. <1.0 cm: OR 2.92, 95% CI: 1.84, 4.64; >2.0 cm vs. <1.0 cm: OR 6.41, 95% CI: 3.30, 12.46) were associated with increased odds of self-detection relative to screening mammogram. The odds of CBE and self-detection as initial modes of breast cancer detection among Black women are independently associated with breast care and breast cancer screening services before diagnosis and with larger tumors at diagnosis.Entities:
Year: 2019 PMID: 31354818 PMCID: PMC6637674 DOI: 10.1155/2019/3529651
Source DB: PubMed Journal: J Oncol ISSN: 1687-8450 Impact factor: 4.375
Sociodemographic characteristics of Black women age 40-75 years in the Women's Circle of Health Study (WCHS), overall and by initial mode of breast cancer detection.
| Overall | Screening mammogram | Clinical breast exam | Self-detection |
| |
|---|---|---|---|---|---|
| (N = 1322) | (n = 725) | (n = 63) | (n = 534) | ||
|
|
|
|
| ||
| Age at diagnosis (years), mean±SD | 54.19±10.7 | 57.35±9.2 | 51.44±11.1 | 50.17±11.1 |
|
| Age at diagnosis (years) |
| ||||
| 40-49 | 325 (24.6) | 147 (20.3) | 17 (27.0) | 161 (30.2) | |
| 50-59 | 431 (32.6) | 248 (34.2) | 17 (27.0) | 166 (31.1) | |
| 60-75 | 449 (34.0) | 318 (43.9) | 17 (27.0) | 114 (21.4) | |
| Marital statusa | 0.494 | ||||
| Married or living as married | 576 (43.6) | 326 (45.0) | 25 (39.7) | 225 (42.1) | |
| Unmarried | 746 (56.4) | 399 (55.0) | 38 (60.3) | 309 (57.9) | |
| Education | 0.390 | ||||
| High school/vocational/technical graduate or below | 538 (40.7) | 311 (42.9) | 25 (39.7) | 202 (37.8) | |
| Some post-secondary education | 327 (24.7) | 167 (23.0) | 13 (20.6) | 147 (27.5) | |
| College graduate or above | 456 (34.5) | 246 (33.9) | 25 (39.7) | 185 (34.6) | |
| Annual household incomeb | 0.224 | ||||
| <$70,000 | 765 (57.9) | 400 (55.2) | 37 (58.7) | 328 (61.4) | |
| ≥$70,000 | 480 (36.3) | 282 (38.9) | 21 (33.3) | 177 (33.2) | |
| Primary health insurance at diagnosisc |
| ||||
| Private | 775 (58.6) | 413 (57.0) | 39 (61.9) | 323 (60.5) | |
| Medicaid | 130 (9.8) | 65 (9.0) | 8 (12.7) | 57 (10.7) | |
| Medicare | 193 (14.6) | 140 (19.3) | 10 (15.9) | 43 (8.1) | |
| Uninsured | 131 (9.9) | 51 (7.0) | 5 (7.9) | 75 (14.0) | |
| Other | 81 (6.1) | 50 (6.9) | 1 (1.6) | 30 (5.6) | |
| Missing | 12 (0.9) | 6 (0.8) | 0 (0.0) | 6 (1.1) |
aThe unmarried category is composed of those who reported being single/never married, separated, divorced, or widowed.
b$70,000 is the median income among households in New Jersey and was used as the cut-point to dichotomize the income variable.
cThe “other” insurance category includes forms of insurance reported by WCHS participants that did not fall into one of the four main categories above and included the following types of insurance coverage: school-provided, national government-provided [foreign country], spousal insurance, health center care, charity care, health savings account, and Veterans Affairs coverage.
Reproductive characteristics and medical history of Black women aged 40-75 years in the WCHS, overall and by initial mode of breast cancer detection.
| Overall | Screening mammogram | Clinical breast exam | Self-detection |
| |
|---|---|---|---|---|---|
| (N = 1322) | (n = 725) | (n = 63) | (n = 534) | ||
|
|
|
|
| ||
| Menopausal status |
| ||||
| Premenopausal | 516 (39.0) | 203 (28.0) | 36 (57.1) | 277 (51.9) | |
| Postmenopausal | 806 (61.0) | 522 (72.0) | 27 (42.9) | 257 (48.1) | |
| Age at menarche (years) | 0.324 | ||||
| <12 | 381 (28.8) | 212 (29.2) | 11 (17.5) | 158 (29.6) | |
| 12-13 | 618 (46.8) | 338 (46.6) | 32 (50.8) | 248 (46.4) | |
| >13 | 323 (24.4) | 175 (24.1) | 20 (31.8) | 128 (24.0) | |
| Parity | 0.428 | ||||
| Nulliparous | 231 (17.5) | 117 (16.1) | 9 (14.3) | 105 (19.7) | |
| 1-2 children | 679 (51.4) | 377 (52.0) | 31 (49.2) | 271 (50.8) | |
| ≥3 children | 412 (31.2) | 231 (31.9) | 23 (36.5) | 158 (29.6) | |
| Age at first birth (years)a | 0.605 | ||||
| <25 | 687 (63.0) | 382 (62.8) | 30 (55.6) | 275 (64.1) | |
| 25-30 | 242 (22.2) | 130 (21.4) | 15 (27.8) | 97 (22.6) | |
| >30 | 162 (14.9) | 96 (15.8) | 9 (16.7) | 57 (13.3) | |
| History of breastfeedinga | 0.458 | ||||
| No | 592 (54.5) | 336 (55.5) | 32 (59.3) | 224 (52.3) | |
| Yes | 495 (45.5) | 269 (44.5) | 22 (40.7) | 204 (47.7) | |
| History of oral contraceptive use | 0.685 | ||||
| No | 933 (70.6) | 505 (69.7) | 42 (66.7) | 386 (72.3) | |
| Yes | 388 (29.4) | 219 (30.2) | 21 (33.3) | 148 (27.7) | |
| History of hormone therapy use |
| ||||
| No | 1084 (82.0) | 556 (76.7) | 57 (90.5) | 471 (88.2) | |
| Yes | 231 (17.5) | 166 (22.9) | 6 (9.5) | 59 (11.1) | |
| Family history of breast cancer | 0.733 | ||||
| No | 1075 (81.3) | 584 (80.6) | 52 (82.5) | 439 (82.2) | |
| Yes | 247 (18.7) | 141 (19.5) | 11 (17.5) | 95 (17.8) | |
| Body mass index (kg/m2) |
| ||||
| <25.0 | 261 (19.7) | 105 (14.5) | 16 (25.4) | 140 (26.2) | |
| 25.0-29.99 | 389 (29.4) | 226 (31.2) | 17 (27.0) | 146 (27.3) | |
| 30.0-34.99 | 312 (23.6) | 189 (26.1) | 14 (22.2) | 109 (20.4) | |
| ≥35.0 | 359 (27.2) | 204 (28.1) | 16 (25.4) | 139 (26.0) |
aAge at first birth and history of breastfeeding data are among parous women only.
Breast care characteristics prior to breast cancer diagnosis and tumor clinicopathologic features among Black women aged 40-75 years in the WCHS, overall and by initial mode of breast cancer detection.
| Overall | Screening mammogram | Clinical breast exam | Self-detection |
| |
|---|---|---|---|---|---|
| (N = 1643) | (n = 725) | (n = 63) | (n = 534) | ||
|
|
|
|
| ||
|
| |||||
| Ever received a doctor's recommendation for a mammogram before breast cancer diagnosis |
| ||||
| No | 274 (20.7) | 103 (14.2) | 16 (25.4) | 155 (29.0) | |
| Yes | 1045 (79.1) | 620 (85.5) | 47 (74.6) | 378 (70.8) | |
| Ever had a routine screening mammogram before breast cancer diagnosis |
| ||||
| No | 174 (13.2) | 37 (5.1) | 16 (25.4) | 121 (22.7) | |
| Yes | 1148 (86.8) | 688 (94.9) | 47 (74.6) | 413 (77.3) | |
| Interval between breast cancer diagnosis and most recent routine screening mammogram |
| ||||
| <1 year | 112 (8.5) | 66 (9.1) | 4 (6.4) | 42 (7.9) | |
| 1 year | 565 (42.7) | 382 (52.7) | 17 (27.0) | 166 (31.1) | |
| >1 year | 377 (28.5) | 186 (25.7) | 17 (27.0) | 174 (32.6) | |
| Unknown | 268 (20.3) | 91 (12.6) | 25 (39.7) | 152 (28.5) | |
| Ever had a doctor perform a clinical breast exam(s) (CBE) before breast cancer diagnosis |
| ||||
| No | 183 (13.8) | 91 (12.6) | 4 (6.4) | 88 (16.5) | |
| Yes – last CBE performed within the last year | 795 (60.1) | 482 (66.5) | 35 (55.6) | 278 (52.1) | |
| Yes – last CBE performed more than one year ago | 332 (25.1) | 146 (20.1) | 23 (36.5) | 163 (30.5) | |
| Ever performed breast self-exams (BSEs) before breast cancer diagnosis |
| ||||
| No | 283 (21.4) | 197 (27.2) | 25 (39.7) | 61 (11.4) | |
| Yes – BSEs performed less than once per month | 375 (28.4) | 184 (25.4) | 24 (38.1) | 167 (31.3) | |
| Yes – BSEs performed at least once per month | 657 (49.7) | 338 (46.6) | 14 (22.2) | 305 (57.1) | |
| Ever diagnosed with a benign breast disease before breast cancer diagnosis |
| ||||
| No | 839 (63.5) | 443 (61.1) | 42 (66.7) | 354 (66.3) | |
| Yes | 476 (36.0) | 281 (38.8) | 20 (31.8) | 175 (32.8) | |
|
| |||||
| Tumor grade |
| ||||
| Well/moderately differentiated | 608 (46.0) | 357 (49.2) | 36 (57.1) | 215 (40.3) | |
| Poorly differentiated | 483 (36.5) | 178 (24.6) | 22 (34.9) | 283 (53.0) | |
| Unknown | 231 (17.5) | 190 (26.2) | 5 (7.9) | 36 (6.7) | |
| SEER summary stage |
| ||||
| In situ | 166 (12.6) | 144 (19.9) | 2 (3.2) | 20 (3.8) | |
| Localized | 718 (54.3) | 427 (58.9) | 37 (58.7) | 254 (47.6) | |
| Regional/distant | 376 (28.4) | 115 (15.9) | 23 (36.5) | 238 (44.6) | |
| Unstaged | 15 (1.1) | 5 (0.7) | 1 (1.6) | 9 (1.7) | |
| Missing | 47 (3.6) | 34 (4.7) | 0 (0.0) | 13 (2.4) | |
| Tumor size (cm) |
| ||||
| <1.0 | 509 (38.5) | 413 (57.0) | 15 (23.8) | 81 (15.2) | |
| 1.0-2.0 | 356 (26.9) | 196 (27.0) | 22 (34.9) | 138 (25.8) | |
| >2.0 | 456 (34.5) | 115 (15.9) | 26 (41.3) | 315 (59.0) | |
| Unknown | 1 (0.1) | 1 (0.1) | 0 (0.0) | 0 (0.0) | |
| Lymph node status |
| ||||
| Negative | 814 (61.6) | 500 (69.0) | 38 (60.3) | 276 (51.7) | |
| Positive | 378 (28.6) | 119 (16.4) | 21 (33.3) | 238 (44.6) | |
| Unknown | 130 (9.8) | 106 (14.6) | 4 (6.4) | 20 (3.8) | |
| Lymphovascular invasion present |
| ||||
| No | 856 (64.8) | 487 (67.2) | 45 (71.4) | 324 (60.7) | |
| Yes | 207 (15.7) | 59 (8.1) | 11 (17.5) | 137 (25.7) | |
| Unknown | 259 (19.6) | 179 (24.7) | 7 (11.1) | 73 (13.7) | |
| Estrogen receptor (ER) status |
| ||||
| ER+ | 972 (73.5) | 573 (79.0) | 56 (88.9) | 343 (64.2) | |
| ER- | 346 (26.2) | 148 (20.4) | 7 (11.1) | 191 (35.8) | |
| Unknown | 4 (0.3) | 4 (0.6) | 0 (0.0) | 0 (0.0) | |
| Molecular subtypea |
| ||||
| ER+/PR+/HER2- | 745 (56.4) | 431 (59.5) | 44 (69.8) | 270 (50.6) | |
| ER+/PR+/HER2+ | 127 (9.6) | 56 (7.7) | 10 (15.9) | 61 (11.4) | |
| ER-/PR-/HER2+ | 78 (5.9) | 33 (4.6) | 1 (1.6) | 44 (8.2) | |
| ER-/PR-/HER2- | 234 (17.7) | 92 (12.7) | 6 (9.5) | 136 (25.5) | |
| Unknown | 138 (10.4) | 113 (15.6) | 2 (3.2) | 23 (4.3) |
aMolecular subtypes were classified using surrogate classifications, based on immunohistochemistry expression of ER and PR, and overexpression of HER2 (by immunohistochemistry and/or fluorescence in situ hybridization) as reported in pathology records.
Age-adjusted associations of sociodemographic, reproductive characteristics and medical history with initial mode of breast cancer detection among Black women aged 40-75 years.
| Clinical breast exam compared to screening mammogram | Self-detection compared to screening mammogram | |
|---|---|---|
| Age-adjusted | Age-adjusted | |
| OR (95% CI) | OR (95% CI) | |
| Marital statusa | ||
| Married or living as married | 1.00 (Referent) | 1.00 (Referent) |
| Unmarried | 1.25 (0.70, 2.24) | 1.27 (0.99, 1.63) |
| Education | ||
| High school/vocational/technical graduate or below | 0.97 (0.5, 1.86) | 1.10 (0.82, 1.46) |
| Some post-secondary education | 0.93 (0.43, 2.01) | 1.31 (0.95, 1.81) |
| College graduate or above | 1.00 (Referent) | 1.00 (Referent) |
| Annual household incomeb | ||
| <$70,000 | 1.37 (0.73, 2.58) |
|
| ≥$70,000 | 1.00 (Referent) | 1.00 (Referent) |
| Primary health insurance at diagnosisc | ||
| Private | 1.00 (Referent) | 1.00 (Referent) |
| Medicaid | 1.30 (0.52, 3.26) | 1.14 (0.75, 1.74) |
| Medicare | 1.47 (0.62, 3.49) | 0.78 (0.51, 1.18) |
| Uninsured | 1.14 (0.38, 3.37) |
|
| Other | 0.27 (0.04, 2.04) | 0.76 (0.45, 1.27) |
| Menopausal Status | ||
| Premenopausal |
| 0.98 (0.66, 1.48) |
| Postmenopausal | 1.00 (Referent) | 1.00 (Referent) |
| Age at menarche (years) | ||
| <12 |
| 0.90 (0.65, 1.25) |
| 12-13 | 0.87 (0.45, 1.66) | 0.90 (0.67, 1.22) |
| >13 | 1.00 (Referent) | 1.00 (Referent) |
| Parity | ||
| Nulliparous | 1.00 (Referent) | 1.00 (Referent) |
| 1-2 children | 1.59 (0.59, 4.25) | 0.88 (0.63, 1.24) |
| ≥3 children | 2.42 (0.88, 6.63) | 1.10 (0.77, 1.59) |
| Age at first birth (years) | ||
| Nulliparous | 1.00 (Referent) | 1.00 (Referent) |
| <25 | 1.84 (0.69, 4.91) | 1.06 (0.75, 1.48) |
| 25-30 | 2.20 (0.75, 6.46) | 0.93 (0.62, 1.41) |
| >30 | 1.59 (0.49, 5.19) | 0.69 (0.44, 1.09) |
| History of breastfeeding | ||
| Nulliparous | 1.00 (Referent) | 1.00 (Referent) |
| No | 2.29 (0.86, 6.08) | 1.03 (0.73, 1.46) |
| Yes | 1.54 (0.55, 4.28) | 0.90 (0.63, 1.28) |
| History of oral contraceptive use | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes | 0.62 (0.34, 1.12) | 0.89 (0.68, 1.17) |
| History of hormone therapy use | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes | 0.52 (0.21, 1.28) |
|
| Family history of breast cancer | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes | 1.05 (0.51, 2.16) | 0.96 (0.7, 1.31) |
| Body mass index (kg/m2) | ||
| <25.0 | 1.2 (0.52, 2.78) |
|
| 25.0-29.99 | 0.69 (0.31, 1.51) | 0.79 (0.57, 1.09) |
| 30.0-34.99 | 1.01 (0.48, 2.16) | 0.72 (0.51, 1.02) |
| ≥35.0 | 1.00 (Referent) | 1.00 (Referent) |
aThe unmarried category is composed of those who reported being single/never married, separated, divorced, or widowed.
b$70,000 is the median income among households in New Jersey and was used as the cut-point to dichotomize the income variable.
cThe “other” insurance category includes forms of insurance reported by WCHS participants that did not fall into one of the four main categories above and included the following types of insurance coverage: school-provided, national government-provided [foreign country], spousal insurance, health center care, charity care, health savings account, and Veterans Affairs coverage.
Age-adjusted associations of breast care characteristics prior to breast cancer diagnosis and tumor clinicopathologic characteristics with initial mode of breast cancer detection among Black women aged 40-75 years.
| Clinical breast exam compared to screening mammogram | Self-detection compared to screening mammogram | |
|---|---|---|
| Age-adjusted | Age-adjusted | |
| OR (95% CI) | OR (95% CI) | |
|
| ||
| Ever received a doctor's recommendation for a mammogram | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes | 0.70 (0.34, 1.47) | 0.73 (0.53, 1.02) |
| Ever had a routine screening mammogram before breast cancer diagnosis | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes |
|
|
| Interval between breast cancer diagnosis and most recent routine screening mammogram | ||
| <1 year | 1.00 (Referent) | 1.00 (Referent) |
| 1 year | 0.84 (0.24, 3.00) | 0.71 (0.45, 1.12) |
| >1 year | 1.99 (0.56, 7.03) | 1.59 (1.00, 2.54) |
| Ever had a doctor perform a clinical breast exam(s) (CBE) before diagnosis | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes – last CBE performed within the last year | 1.47 (0.43, 4.99) |
|
| Yes – last CBE performed more than one year ago |
| 1.13 (0.76, 1.67) |
| Ever performed breast self-exams (BSEs) before breast cancer diagnosis | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes – BSEs performed less than once per month | 1.04 (0.54, 2.02) |
|
| Yes – BSEs performed at least once per month |
|
|
| Ever diagnosed with a benign breast disease before breast cancer diagnosis | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes | 0.84 (0.46, 1.55) | 0.90 (0.7, 1.17) |
|
| ||
| Tumor grade | ||
| Well/moderately differentiated | 1.00 (Referent) | 1.00 (Referent) |
| Poorly differentiated | 0.95 (0.50, 1.81) |
|
| SEER summary stage | ||
| In situ |
|
|
| Localized | 1.00 (Referent) | 1.00 (Referent) |
| Regional/distant |
|
|
| Tumor size (cm) | ||
| <1.0 | 1.00 (Referent) | 1.00 (Referent) |
| 1.0-2.0 |
|
|
| >2.0 |
|
|
| Lymph node status | ||
| Negative | 1.00 (Referent) | 1.00 (Referent) |
| Positive |
|
|
| Lymphovascular invasion present | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes | 1.92 (0.88, 4.18) |
|
| Estrogen receptor (ER) statusa | ||
| ER+ | 1.00 (Referent) | 1.00 (Referent) |
| ER- | 0.40 (0.16, 1.03) |
|
| Molecular subtypeb | ||
| ER+/PR+/HER2- | 1.00 (Referent) | 1.00 (Referent) |
| ER+/PR+/HER2+ | 1.57 (0.69, 3.56) | 1.50 (0.98, 2.31) |
| ER-/PR-/HER2+ | 0.32 (0.04, 2.43) |
|
| ER-/PR-/HER2- | 0.48 (0.17, 1.39) |
|
aAs shown in Table 3, percent unknown for tumor characteristics in the overall study sample was as follows: tumor grade, 17.5%; SEER summary stage, 3.6%; tumor size (cm), 0.1%; lymph node status, 9.8%; lymphovascular invasion present, 19.6%; ER status, 0.3%; molecular subtype, 10.4%.
bMolecular subtypes were classified using surrogate classifications, based on immunohistochemical expression of ER and PR and overexpression or amplification of HER2 (by immunohistochemistry or fluorescence in situ hybridization) as reported in pathology records.
Multivariable logistic regression analysis of the factors associated with mode of detection among Black women aged 40-75 years.
| Characteristic | Clinical breast exam compared to screening mammogram | Self-detection compared to screening mammogram |
|---|---|---|
| Multivariable-adjusted | Multivariable-adjusted | |
| OR (95% CI) | OR (95% CI) | |
| Primary health insurance at diagnosis | ||
| Private | 1.00 (Referent) | 1.00 (Referent) |
| Medicaid | 0.99 (0.31, 3.15) | 1.03 (0.59, 1.82) |
| Medicare | 1.84 (0.63, 5.38) | 0.83 (0.48, 1.43) |
| Uninsured | 0.58 (0.14, 2.37) | 1.38 (0.77, 2.47) |
| Other | 0.31 (0.04, 2.63) | 0.92 (0.46, 1.83) |
| Body mass index (kg/m2) | ||
| <25.0 | 1.33 (0.49, 3.62) |
|
| 25.0-29.99 | 0.79 (0.32, 1.95) | 1.07 (0.70, 1.64) |
| 30.0-34.99 | 1.22 (0.50, 2.97) | 0.80 (0.50, 1.26) |
| ≥35.0 | 1.00 (Referent) | 1.00 (Referent) |
| History of hormone therapy use | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes | 0.61 (0.23, 1.63) |
|
| Ever had a routine screening mammogram before breast cancer diagnosis | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes |
| 0.52 (0.27, 1.00) |
| Ever had a doctor perform a clinical breast exam(s) (CBE) before breast cancer diagnosis | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes – last CBE performed within the last year | 4.33 (0.90, 20.83) |
|
| Yes – last CBE performed more than one year ago |
| 1.28 (0.74, 2.20) |
| Ever performed breast self-exams (BSEs) before breast cancer diagnosis | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes – BSEs performed less than once per month | 0.92 (0.42, 2.01) |
|
| Yes – BSEs performed at least once per month |
|
|
|
| ||
| Tumor gradea | ||
| Well/moderately differentiated | 1.00 (Referent) | 1.00 (Referent) |
| Poorly differentiated | 0.65 (0.28, 1.47) | 1.19 (0.80, 1.77) |
| SEER summary stage | ||
| In situ | 0.44 (0.02, 9.20) | 0.65 (0.21, 2.05) |
| Localized | 1.00 (Referent) | 1.00 (Referent) |
| Regional/distant | 4.39 (0.78, 24.83) | 1.98 (0.92, 4.27) |
| Tumor size (cm)a | ||
| <1.0 | 1.00 (Referent) | 1.00 (Referent) |
| 1.0-2.0 | 2.13 (0.83, 5.44) |
|
| >2.0 | 3.17 (0.88, 11.42) |
|
| Lymph node statusa | ||
| Negative | 1.00 (Referent) | 1.00 (Referent) |
| Positive | 1.54 (0.54, 4.34) | 1.62 (0.93, 2.81) |
| Lymphovascular invasion presenta | ||
| No | 1.00 (Referent) | 1.00 (Referent) |
| Yes | 1.18 (0.48, 2.87) | 1.35 (0.84, 2.18) |
| Estrogen receptor (ER) statusa | ||
| ER+ | 1.00 (Referent) | 1.00 (Referent) |
| ER- | - | 1.13 (0.42, 3.07) |
| Molecular subtypea,b | ||
| ER+/PR+/HER2- | 1.00 (Referent) | 1.00 (Referent) |
| ER+/PR+/HER2+ | 1.44 (0.53, 3.91) | 1.08 (0.61, 1.91) |
| ER-/PR-/HER2+ | - | 1.44 (0.45, 4.63) |
| ER-/PR-/HER2- | - | 1.69 (0.59, 4.82) |
Note: odds ratios (ORs) and 95% confidence intervals (Cis) were generated using multivariable models, mutually adjusting for all variables shown in the table as well as for age.
aAs shown in Table 3, percent unknown for tumor characteristics in the overall study sample was as follows: tumor grade, 17.5%; SEER summary stage, 3.6%; tumor size (cm), 0.1%; lymph node status, 9.8%; lymphovascular invasion present, 19.6%; ER status, 0.3%; molecular subtype, 10.4%.
bMolecular subtypes were classified using surrogate classifications, based on immunohistochemical expression of ER and PR, and overexpression or amplification of HER2 (by immunohistochemistry or fluorescence in situ hybridization) as reported in pathology records.